{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-082709","form_type":"8-K","ticker":"EQ","cik":"0001746466","company_name":"Equillium, Inc.","filed_at":"2024-04-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.867201+00:00","generated_at":"2026-06-04T04:47:11.109887+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Equillium reports positive Phase 1b itolizumab data in lupus nephritis","bullets":["Topline data: 16 patients; baseline mean UPCR 4.9 g/g → ~73% reduction; overall response rate 81.3% (CR+PR).","Complete response in 37.5%, partial response in 43.8%; ORR comparable to Phase 3 AURORA1 voclosporin study.","Safety: mostly mild/moderate TEAEs (lymphopenia, peripheral edema); no treatment-related serious AEs; >80% steroid taper.","Data triggers Ono's option to acquire itolizumab; decision expected H2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-082709","json":"https://secwatch.observer/filing/0001193125-24-082709.json","markdown":"https://secwatch.observer/filing/0001193125-24-082709.md","text":"https://secwatch.observer/filing/0001193125-24-082709.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1746466/000119312524082709/0001193125-24-082709-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1746466/000119312524082709/d819425d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T04:47:11.109887+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}